Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Isabelle Hennebelle"'
Autor:
Pauline Claraz, Elina Wolff, Florent Puisset, Charlotte Vert, Isabelle Riff, Jean-Marie Canonge, Isabelle Hennebelle, Anaïs Grand, Sophie Perriat, Yann Cretu
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 77(22)
Purpose Infusion of cytotoxic drugs carries the risk of occupational exposure of healthcare workers. Since disconnecting an infusion line is a source of contamination, flushing of tubing after infusion of cytotoxic agents is recommended, but the opti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f22fe3bf32ed2aad0b5ae882b658a372
https://pubmed.ncbi.nlm.nih.gov/33124655
https://pubmed.ncbi.nlm.nih.gov/33124655
Autor:
C. Garnier Tixidre, Caroline Delmas, J.-P. Delord, Etienne Chatelut, Isabelle Lochon, Agnes Bonadona, Anthony Goncalves, Nicolas Penel, Fabienne Thomas, Isabelle Hennebelle, C. Dhelens, Christine Toulas
Publikováno v:
Clinical Pharmacology & Therapeutics. 99:235-242
Despite the growing evidence that dihydropyrimidine dehydrogenase deficiency (DPD, encoded by the DPYD gene) confers a higher risk of developing severe toxicity, most patients are not screened for DPD deficiency before fluoropyrimidine treatment. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de295f3b3c869f0954909befdfbbc883
https://doi.org/10.1002/cpt.210
https://doi.org/10.1002/cpt.210
Autor:
Jean-Marc Soulat, Aude Levant-Herin, Isabelle Hennebelle, Dana Macovei, Maguy Metais, Monique Marpinard, Yann Cretu
Publikováno v:
Archives des Maladies Professionnelles et de l'Environnement. 79:339-340
Objet Dans la continuite des recommandations pour la manipulation des cytotoxiques debutees en 2013, la derniere etape est constituee par l’elimination des dechets de chimiotherapie et la mise en place de kit d’intervention en cas d’epanchement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b158e66b31f975295232cca00bf93579
https://doi.org/10.1016/j.admp.2018.03.285
https://doi.org/10.1016/j.admp.2018.03.285
Autor:
Isabelle Hennebelle, Christine Chevreau, Sarah Bétrian, Etienne Chatelut, Sophie Le Guellec, Fabienne Thomas, Anne-Pascale Laurenty, Chantal Le Guellec
Publikováno v:
Pharmacogenomics. 14:1389-1396
We describe here the case of a 60-year old male patient treated for an extensive local progression of a pleiomorphic sarcoma on the right tibial crest with second-line trabectedin. Two cycles were administrated before a major liver toxicity was retri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b82aa0f2c81537938afb8a1e2972a7c
https://doi.org/10.2217/pgs.13.124
https://doi.org/10.2217/pgs.13.124
Autor:
Chaza El Hannani, Isabelle Hennebelle, Roger Faroux, Mireille Francoual, Eric Francois, J.H. Jacob, Gérard Milano, Marie-Christine Etienne-Grimaldi, Jean-Louis Formento, Jaafar Bennouna, Jean-Yves Douillard, Etienne Chatelut
Publikováno v:
British Journal of Clinical Pharmacology. 73:776-785
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Previous pharmacogenetic studies have reported the potential predictive value of thymidylate synthase (TYMS) polymorphisms or methylenetetrahydrofolate reductase (MTHFR) polymorphisms for the efficacy of 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b824e674a121b564c994aa10a69cd552
https://doi.org/10.1111/j.1365-2125.2011.04141.x
https://doi.org/10.1111/j.1365-2125.2011.04141.x
Autor:
Melanie White-Koning, Jean Pierre Delord, Fabienne Thomas, Gilles Vassal, Etienne Chatelut, Elodie Civade, Marie-Cécile Le Deley, Birgit Geoerger, Isabelle Hennebelle
Publikováno v:
Clinical Cancer Research. 17:4862-4871
Purpose: The aim of this pharmacokinetic–pharmacodynamic (PK–PD) analysis was to evaluate the pharmacologic characteristics of erlotinib and its main metabolite (OSI-420) in pediatric patients compared with those in adult patients. Experimental D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f595c8097104b14bb79d462c4417394
https://doi.org/10.1158/1078-0432.ccr-10-3278
https://doi.org/10.1158/1078-0432.ccr-10-3278
Autor:
Adil Benlyazid, Etienne Chatelut, Fabienne Thomas, Isabelle Hennebelle, Melanie White-Koning, Philippe Rochaix, Jean Pierre Delord, Jean-Louis Lefebvre, Jérôme Sarini, Laurence Malard
Publikováno v:
European Journal of Cancer. 45:2316-2323
A clinical study was conducted to determine the safety and efficacy of neoadjuvant erlotinib treatment in patients with head and neck squamous cell carcinoma [Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treatment with erlotini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e2b87111774d44f1bb4f10fee106176
https://doi.org/10.1016/j.ejca.2009.05.007
https://doi.org/10.1016/j.ejca.2009.05.007
Publikováno v:
Anti-Cancer Drugs. 12:741-751
The in vitro and in vivo combination of oxaliplatin and irinotecan was investigated in a panel of four human colon cancer cell lines and their counterpart xenografts. In vitro and in vivo experiments demonstrated a synergistic or additive interaction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942c3483255fc1cce6ab3d6a668e796b
https://doi.org/10.1097/00001813-200110000-00006
https://doi.org/10.1097/00001813-200110000-00006
Autor:
Pierre Canal, Catherine Terret, Etienne Chatelut, Sylvie Guichard, Isabelle Hennebelle, Roland Bugat
Publikováno v:
Anti-Cancer Drugs. 11:465-470
Irinotecan (CPT-11) is a topoisomerase I inhibitor commonly used in the treatment of colorectal tumors. It is a prodrug, converted to an active metabolite, SN-38, by carboxylesterases (CEs). CEs are ubiquitary enzymes that react with numerous substra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7f7998f8f97ddcda230bb06a3178ac1
https://doi.org/10.1097/00001813-200007000-00007
https://doi.org/10.1097/00001813-200007000-00007
Autor:
P Chevreau, Sylvie Guichard, Isabelle Hennebelle, Etienne Chatelut, Janick Selves, Isabelle Lochon, Roland Bugat, Catherine Terret, Pierre Canal, E Frétigny
Publikováno v:
British Journal of Cancer
CPT-11 is a prodrug activated by carboxylesterases to the active metabolite SN-38 which is a potent inhibitor of topoisomerase I. CPT-11 is of clinical interest in the treatment of colorectal cancer. We evaluated the activities of CPT-11 converting c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee70de2059494542d0f52c72ae0eb5a8
http://europepmc.org/articles/PMC2362335
http://europepmc.org/articles/PMC2362335